



Pharmascience Inc. of Canada and Korea Kolmar Holdings announce agreement to create Pharmascience Korea to bring Canadian Bio-Equivalent Medicines to Korea

Companies to have equal share of new company that plans to launch products in 2014

Seoul, Republic of Korea – January 2, 2013 – Canada’s Pharmascience Inc. and Korea Kolmar Holdings announced today that they have entered into an agreement to create a new company, Pharmascience Korea, which expects to launch Canadian-made bio-equivalent medicines in Korea in 2014.

Privately held Pharmascience Inc. was founded in 1983 and is now the third-largest bio-equivalent medicines manufacturer in Canada. Through its International division, it has a presence in more than 60 countries around the world.

Korea Kolmar Holdings’ subsidiary Korea Kolmar was founded in 1990 and is Korea’s leading cosmetics manufacturer, responsible for almost one-third of all cosmetics sold in Korea. In 2002, it started its Pharmaceutical division which now accounts for 30 per cent of company sales. Both Korea Kolmar Holdings and Korea Kolmar are publicly traded on the KRX (Korea Exchange).

Pharmascience and Korea Kolmar Holdings will contribute equal capital amounts into Pharmascience Korea, which will seek approval of the Korea Food and Drug Administration to market a variety of Pharmascience bio-equivalent medicines in Korea by mid-2014. The initial product portfolio will focus on central nervous system medications to treat a variety of psychiatric disorders. The products will be manufactured by Pharmascience at its state-of-the-art facility in Montreal, Canada. The facility is fully certified by the Canadian Government.

“We are very pleased to announce this important partnership with Pharmascience which will allow us to bring their high-quality, Canadian-made medicines to patients in Korea,” said Donghan Yoon, Founder and Chairman of the Board of Korea Kolmar Holdings. “This will add greatly to our activities in the Korean pharmaceuticals market and have a positive effect on both Korea Kolmar Holdings and Korea Kolmar.”

“This collaboration with Korea Kolmar Holdings allows Pharmascience to enter the important Korean pharmaceutical market in a major way, consistent with our strategy of expanding the Pharmascience presence internationally,” said David Goodman, Chief Executive Officer of Pharmascience Inc. “We look forward to working together with Korea Kolmar Holdings to make our products available for the benefit of Korean patients.”

“Kolmar is a very successful company in Korea with great reputation and values like those of Pharmascience, making for a great fit between the two organizations,” said Trevor Arsenault, Vice-President, Pharmascience International Division. “Their local expertise is a key asset in this partnership and we anticipate great success from this joint endeavour.”

The Korean bio-equivalent drug market is ranked the 13th largest in the world while that of Canada is ranked 10th. Pharmascience Korea will have its initial headquarters at the offices of Korea Kolmar in Seoul. Management of the new company will be announced shortly.

COSMO USA IBRC, Inc. (www.cosmo-usa.com), a life sciences industry consulting company, served an integral role in bringing Pharmascience and Kolmar Korea together for this agreement. Important support was also received from KOTRA (Korea Trade-Investment Promotion Agency) Toronto of the Consulate General of the Republic of Korea, Commercial Section, as well as the Canadian Trade Commissioner in Canada and South Korea.

About Korea Kolmar Co. Ltd.

A subsidiary of Korea Kolmar Holdings, Korea Kolmar Co. Ltd was founded in 1990 and is a major manufacturer of cosmetics and pharmaceutical products. It is Korea’s largest cosmetics manufacturer, responsible for almost one third of all cosmetics sold in the country. Its Pharmaceutical division is responsible for about 30 per cent of company sales. The company has 700 employees and had revenues in 2011 of US\$300 million, an increase of 20 per cent over 2010. www.kolmar.co.kr/ENG/company/ceo.html

About Pharmascience Inc.

Founded in 1983 in Montreal, where its headquarters remain, privately held Pharmascience Inc. is Canada’s third largest manufacturer of bio-equivalent medicines, with annual sales exceeding US\$700 million. Through its International Division, its products are exported to 60 countries around the world. It also makes and distributes patented prescription and over-the-counter treatments through its Pendopharm division while its Aegera Therapeutics business unit is researching innovative new biotechnology therapies. Pharmascience is one of Canada’s leading corporate investors in research and development and employs more than 1,300 people, primarily in Montreal. www.pharmascience.com
